In this review we explore the 6-year results for MiSight 1 day recently presented at the 2020 American Academy of Optometry meeting. Based on the abstract, children who were older at initial fitting (11-15 years) progressed similarly over 3 years to matched children who were treated for 6 years, indicating that older children could still gain a treatment effect from MiSight 1 day.
There’s a common clinical belief that orthokeratology doesn’t work as well in lower myopes for myopia control. This is even sometimes included in conference presentations as prescribing advice. Is orthokeratology useful for control of low myopia? Here’s what’s fact and what’s fiction, when considering its efficacy for low vs high myopia, and orthokeratology vs multifocal contact lens myopia control.
Esophoria at near is a risk factor for myopia development and progression. Does it need to be managed in an emmetropic patient without symptoms? Is this patient a pre-myope, and how should this factor into management? Read this interesting clinical case, where colleagues discuss whether to intervene or not, and how to potentially manage both myopia risk and binocular vision.
When atropine isn’t working as a monotherapy, is it valuable to combine it with a myopia controlling contact lens? Could switching from atropine to a contact lens be the better option? In this post on the Facebook discussion group, a colleague sought opinions on combining atropine and MiSight contact lenses.
This research summary describes the major multifocal contact lens (MFCL) research studies for myopia control, and what we still need to learn. From the first studies only a decade ago, to wearing time, commercially available lenses, the influence of BV, novel designs and more, this comprehensive review will get you all the way up to date on MFCLs.